Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Valera Health, established in 2015, operates a behavioral healthcare platform that focuses on delivering personalized mental health services. By leveraging mobile technology, the platform facilitates seamless connections between patients and care teams, ensuring that care is accessible whenever and wherever it is needed. Valera Health's approach combines therapy and medication management, providing comprehensive behavioral health care tailored for employers. This enables employees to quickly access mental health resources while maintaining consistent communication with their care teams. The platform also offers real-time insights into patient needs, allowing care managers to implement timely and personalized interventions to prevent more serious health issues.
Clever Care Health Plan, Inc. provides healthcare insurance plans to members that connect the benefits of Eastern and Western medicine. It offers plans for acupuncture, herbal remedies, and exercises, such as tai chi and qi gong; and treatments, including cupping and moxibustion. The company sells its products through brokers and sales agents. Clever Care Health Plan, Inc. was incorporated in 2018 and is headquartered in Westminster, California with an additional office in Arcadia, California.
Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Upward Health Inc. is a specialty care coordination organization that focuses on delivering integrated and home-based medical and behavioral care for individuals struggling with mental illness and substance abuse disorders. The company collaborates with health plans and healthcare providers to support high-risk patients, ensuring they receive comprehensive care tailored to their needs. By coordinating with caregivers, primary care physicians, and various medical and behavioral health specialists, Upward Health aims to facilitate recovery and help patients transition back into their communities effectively. Founded in 2017 and based in Providence, Rhode Island, Upward Health was previously known as BehaveCare Inc. before rebranding in July 2019.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Valera Health, established in 2015, operates a behavioral healthcare platform that focuses on delivering personalized mental health services. By leveraging mobile technology, the platform facilitates seamless connections between patients and care teams, ensuring that care is accessible whenever and wherever it is needed. Valera Health's approach combines therapy and medication management, providing comprehensive behavioral health care tailored for employers. This enables employees to quickly access mental health resources while maintaining consistent communication with their care teams. The platform also offers real-time insights into patient needs, allowing care managers to implement timely and personalized interventions to prevent more serious health issues.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Willow is a female technology company that develops an in-bra wearable breast pump. Its breast pumps are cordless and spill-proof. It also tracks milk output through a mobile application along with an online portal, enabling mothers to pump anywhere without hassle. The company was founded in 2014 and is headquartered in Mountain View, California.
ControlRad Systems, Inc. is a medical device company based in Radnor, Pennsylvania, focused on developing systems that minimize radiation exposure during fluoroscopic procedures. Established in 2011, the company offers innovative solutions for both mobile and fixed C-arm systems. Its manually controlled region of interest (ROI) product enables physicians to customize the radiation field by identifying specific areas of focus manually. In contrast, the automatically controlled ROI product uses eye-tracking technology, allowing physicians to direct radiation to the area of interest based on their gaze, thereby optimizing radiation dosage while protecting peripheral regions. ControlRad aims to significantly reduce the lifetime risk of radiation exposure for patients and healthcare professionals without compromising image quality or workflow efficiency.
RxWare is a company that specializes in developing a mobile patient platform designed to optimize patient services for specialty pharmaceuticals. Founded in 2013 and headquartered in Wilmington, Delaware, RxWare's mobile intelligence platform provides a comprehensive technology framework that personalizes patient services. Its application serves individuals with diabetes, offering resources on symptoms, management, and diet to help users lower their A1C levels. By integrating behavioral insights with community features and user functionality, RxWare enables patient programs to effectively learn, adapt, and respond to the unique health needs and circumstances of patients, thereby enhancing their overall healthcare experience.
ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].
Science Exchange, Inc. operates an online marketplace designed to facilitate collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and headquartered in Palo Alto, California, the platform allows researchers to search for scientific services, compare pricing, and access quality testimonials, streamlining the procurement process. Additionally, Science Exchange offers an enterprise dynamic report tool that helps pharmaceutical and biotechnology companies track key performance indicators related to their outsourced research and development investments. By automating various collaborative tasks such as obtaining quotes, managing projects, and processing payments, the marketplace enhances R&D productivity while ensuring data security and regulatory compliance.
Science Exchange, Inc. operates an online marketplace designed to facilitate collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and headquartered in Palo Alto, California, the platform allows researchers to search for scientific services, compare pricing, and access quality testimonials, streamlining the procurement process. Additionally, Science Exchange offers an enterprise dynamic report tool that helps pharmaceutical and biotechnology companies track key performance indicators related to their outsourced research and development investments. By automating various collaborative tasks such as obtaining quotes, managing projects, and processing payments, the marketplace enhances R&D productivity while ensuring data security and regulatory compliance.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
SubjectWell is a company that specializes in patient recruitment for clinical trials through its innovative platform. The platform focuses on delivering highly qualified referrals, ensuring that healthcare clients can efficiently find suitable participants for their studies. By offering a risk-free marketplace for clinical trial recruitment, SubjectWell streamlines the process of screening and enrolling patients, which helps clients complete their studies more quickly. This approach addresses the common challenges in clinical trial recruitment, ultimately contributing to the advancement of medical research and patient care.
CredSimple is an NCQA certified credentialing and provider data management solution. They combine software and services to deliver a truly transformative level of service to their clients. Their clients enjoy a 10x improvement in credentialing turnaround times, 15x improvement in credentialing efficiency as compared to industry standards. They help payers and provider organizations to eliminate compliance risk, streamline operations and manage their providers better than ever before.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.
Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Nebula Genomics, founded in 2016 and based in San Francisco, California, is a company focused on human genome sequencing and health data. It aims to create a comprehensive and trusted marketplace for genomic and health data, facilitating access for consumers, researchers, and the medical community. Utilizing blockchain technology, Nebula Genomics empowers individuals to control their genomic data while receiving compensation for its use. The marketplace aggregates extensive genetic information, which researchers can analyze to enhance drug development and streamline clinical trials, ultimately contributing to personalized medicine. The company's innovative DNA sequencing technology allows for the examination of all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, enabling clients to explore genetic variants comprehensively. Nebula Genomics was co-founded by Harvard genomics pioneer George Church and has received backing from notable investors.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.
NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.
Neuspera Medical Inc. specializes in the development and manufacture of ultra-miniaturized implantable devices designed for neuromodulation therapy, often referred to as "electroceuticals." Utilizing licensed mid-field powering technology, these devices leverage the body as a natural waveguide to deliver energy effectively. Founded in 2013 and based in San Jose, California, Neuspera aims to enhance the quality of life for patients dealing with chronic illnesses by providing less invasive and adaptable treatment options. The company's innovative approach allows for deeper implantation of its devices, offering patients new possibilities in managing their health conditions.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Cartiva, Inc. is a medical device company based in Alpharetta, Georgia, focused on developing and marketing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage injuries. Founded in 2011 as a spin-off from Carticept Medical, the company offers the Cartiva Synthetic Cartilage Implant (SCI), designed to replace damaged cartilage surfaces in joints such as the foot, ankle, and knee. This organic polymer-based biomaterial aims to restore natural joint structure, alleviate pain, and enhance functionality. In addition to the SCI, Cartiva provides the ProxiFuse Hammertoe Correction System, which assists in the fixation and reconstruction of lesser toes after correction procedures. The company's products are distributed internationally, including regions such as Brazil, Canada, and the United Kingdom. Cartiva is dedicated to improving patient quality of life through effective treatment options and is backed by a team of experienced professionals in the orthopedic field.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
Science Exchange, Inc. operates an online marketplace designed to facilitate collaboration between researchers and scientific service providers, including academic and government laboratories. Founded in 2011 and headquartered in Palo Alto, California, the platform allows researchers to search for scientific services, compare pricing, and access quality testimonials, streamlining the procurement process. Additionally, Science Exchange offers an enterprise dynamic report tool that helps pharmaceutical and biotechnology companies track key performance indicators related to their outsourced research and development investments. By automating various collaborative tasks such as obtaining quotes, managing projects, and processing payments, the marketplace enhances R&D productivity while ensuring data security and regulatory compliance.
DOTS Technology Corp, founded in 2013 and located in Natick, Massachusetts, operates a diagnostic platform designed to assist consumers with food allergies. The company is focused on developing a food allergen detection system that allows users to test food on the spot, providing immediate information to enhance decision-making and improve the overall quality of life for individuals affected by food allergies. By advancing point-of-care detection technology, DOTS aims to address the needs of millions of consumers and has applications in both consumer and industrial sectors.
GlySens Incorporated develops ICGM System, a fully-implanted continuous glucose monitoring system intended to improve the lives of people with diabetes. The company was founded in 1997 and is based in San Diego, California.
Personal Genome Diagnostics develops a patient-specific analysis of the cancer genome by using advanced tools and technologies. They were the first to sequence and analyze whole human cancer exomes and subsequently identified many alterations responsible for the development of cancer. They have described the principles underlying the genetic basis of human cancer and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Through PGDx, our founders bring their proprietary methods and expertise to research teams worldwide. The services help oncologists and translational scientists sequence and analyze cancer genomes and identify mutations to characterize aspects of the disease. Their expertise in genome analysis ranges from sample preparation and sequencing to data interpretation and analysis. They specialize in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and have developed novel technologies for non-invasive “liquid biopsy” approaches in cancer. Personal Genome Diagnostics was founded in 2010 and is based in Baltimore, Maryland, United States.
Cureatr Inc. offers a mobile care coordination solution aimed at improving medication management for healthcare providers. By integrating HIPAA-secure text messaging with workflow navigation tools, Cureatr facilitates efficient communication among medical teams. The platform is accessible on Web, Android, and iPhone devices, ensuring real-time, universal access to accurate medication data for over 265 million patients. The company addresses the significant challenges of suboptimal medication management in the United States, which leads to substantial healthcare costs and mortality. With a focus on high-quality interventions provided by board-certified telepharmacists, Cureatr aims to enhance patient safety and reduce hospitalizations. Established in 2011, the company is headquartered in New York, New York.
Coravin, Inc. specializes in designing and marketing innovative wine access systems for a variety of customers, including wine enthusiasts, restaurants, wine stores, and wineries. Founded in 2011 and based in Burlington, Massachusetts, the company offers a unique technology that allows users to pour wine by the glass without removing the cork, thereby preserving the wine's quality and aging process. Their product line includes the Coravin Wine Preservation Opener, along with various accessories such as wine access needles, capsules, clamps, and carry cases. This technology enables customers to enjoy fine wines without committing to an entire bottle, ensuring that the wine remains sealed and protected from air and moisture.
ClarVista Medical, Inc. is a California-based company that specializes in developing innovative products for ophthalmic conditions. Founded in 2012 as a spin-off from a medical device incubator, the company focuses on its flagship product, the HARMONI modular intraocular lens system. This system is designed to optimize vision during cataract surgery by allowing for the initial positioning of the lens and the easy exchange of the lens optic, thus enabling healthcare practitioners to tailor procedures to meet individual patient needs. ClarVista Medical has established a robust portfolio of intellectual property and has conducted clinical studies to validate its technology. The company has secured significant funding to advance the development of the HARMONI system and to pursue necessary regulatory approvals.
Cartiva, Inc. is a medical device company based in Alpharetta, Georgia, focused on developing and marketing innovative solutions for orthopedic surgeons and patients suffering from osteoarthritis and cartilage injuries. Founded in 2011 as a spin-off from Carticept Medical, the company offers the Cartiva Synthetic Cartilage Implant (SCI), designed to replace damaged cartilage surfaces in joints such as the foot, ankle, and knee. This organic polymer-based biomaterial aims to restore natural joint structure, alleviate pain, and enhance functionality. In addition to the SCI, Cartiva provides the ProxiFuse Hammertoe Correction System, which assists in the fixation and reconstruction of lesser toes after correction procedures. The company's products are distributed internationally, including regions such as Brazil, Canada, and the United Kingdom. Cartiva is dedicated to improving patient quality of life through effective treatment options and is backed by a team of experienced professionals in the orthopedic field.
Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.
VytronUS, Inc. manufactures and markets cardiac medical devices. VytronUS, Inc. was formerly known as CardionUS, Inc. The company was founded in 2006 and is based in Sunnyvale, California.
Ivantis Inc. is dedicated to developing innovative treatments for primary open angle glaucoma, a condition affecting over 60 million people globally. The company has created an intracanalicular scaffold or implantable device designed to alleviate high intraocular pressure in patients, offering a less invasive and more effective therapeutic option. Founded in 2007 and based in Irvine, California, Ivantis also provides a Session Persistence Server, which safeguards telnet task workers against data loss due to network issues and ensures terminal emulation users maintain productivity across various devices and operating systems. As Ivantis advances its glaucoma treatment solutions, it aims to expand its focus to other debilitating ophthalmic diseases. The company primarily serves ophthalmology specialists in the United States, providing its solutions for use in clinical trials.
RxWare is a company that specializes in developing a mobile patient platform designed to optimize patient services for specialty pharmaceuticals. Founded in 2013 and headquartered in Wilmington, Delaware, RxWare's mobile intelligence platform provides a comprehensive technology framework that personalizes patient services. Its application serves individuals with diabetes, offering resources on symptoms, management, and diet to help users lower their A1C levels. By integrating behavioral insights with community features and user functionality, RxWare enables patient programs to effectively learn, adapt, and respond to the unique health needs and circumstances of patients, thereby enhancing their overall healthcare experience.
Nuvaira, Inc. is a medical device company focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). The company has created a novel, catheter-based Lung Denervation System designed to address airway nerve hyperactivity, a common issue in patients with COPD and asthma. This minimally invasive procedure targets the parasympathetic nerves of the lungs, aiming to enhance lung function, improve exercise capacity, and elevate the quality of life for affected individuals. Founded in 2008 and headquartered in Minneapolis, Minnesota, Nuvaira was previously known as Holaira, Inc. before rebranding in June 2017.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.
MC10, Inc. specializes in developing and selling wearable medical sensors that capture clinical-grade biometric and physiological data for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers several innovative products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, a rehabilitation device for orthopedic surgery; WiSP, which provides cardiac monitoring and ECG recording; and BioStampMD, a flexible sensor designed to conform to the human body for comprehensive data collection. The BioStamp system enhances data acquisition by allowing for discreet and comfortable wear, thus facilitating targeted measurements of muscle activation and movement. MC10's dedication to creating flexible, conformal electronics aims to improve the quality of life by seamlessly integrating technology with human activity.
Transactis, Inc. is a provider of Software-as-a-Service electronic bill presentment and payment solutions in the United States, helping businesses transition from traditional paper-based processes to efficient digital alternatives. The company's primary offering, BillerIQ, is a cloud-based platform that allows businesses to issue electronic bills and invoices and accept payments through various channels, including online, phone, and mobile devices. Additionally, Transactis offers DocumentIQ, a digital document management solution for transforming and archiving documents. The company serves a diverse range of sectors, including financial services, healthcare, education, and utilities, and operates exclusively through a network of resellers, such as financial institutions and technology companies. Transactis is committed to meeting stringent regulatory and compliance standards. Established in 2001 and based in New York, Transactis operates as a subsidiary of Mastercard Incorporated.
NeoTract, Inc. develops surgical devices for urological and gynecological disorders.